Table 2.
Base-case results of the cost-effectiveness analysis.
| Colon cancer burdena |
LYs per treated patient (years) |
QALYs per treated patient (years) |
Costs per treated patient (€) |
Incremental NMBb | ICER in €/QALY (quadrant) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recurrences | Deaths | Undiscounted | Discounted | Undiscounted | Discounted | Undiscounted | Discounted | |||
| CAPOX | ||||||||||
| 6-month strategy | 369 | 316 | 9.09 | 8.05 | 7.60 | 6.71 | 43,328 | 41,257 | Reference | Reference |
| 3-month strategy | 369 | 316 | 9.09 | 8.05 | 7.60 | 6.80 | 39,640 | 37,645 | 8454 | −37,308 (SE)c |
| FOLFOX | ||||||||||
| 6-month strategy | 369 | 316 | 9.09 | 8.05 | 7.60 | 6.71 | 49,301 | 47,135 | Reference | Reference |
| 3-month strategy | 457 | 393 | 8.36 | 7.43 | 6.99 | 6.19 | 46,632 | 44,389 | −23,189 | 5293 (SW) |
Total during the lifetime of a cohort of 1000 treated patients.
At a willingness to pay of €50,000/QALY
ICER indicates that the 3-month strategy is more effective and less costly compared with 6 months. In other words, you save €37,308 to gain 1 QALY.
CAPOX, capecitabine plus oxaliplatin; FOLFOX, fluorouracil, leucovorin and oxaliplatin; ICER, incremental cost-effectiveness ratio; LYs, life-years; NMB, net monetary benefit; QALYs, quality-adjusted life-years; SE, the strategy is located in the southeast quadrant of the cost-effectiveness plane, indicating that a strategy is less costly and more effective compared with the reference strategy; SW, the strategy is located in the southwest quadrant of the cost-effectiveness plane, indicating that a strategy is less costly and less effective compared with the reference strategy.